The fourth in this week’s series, building on earlier pieces, brings the focus squarely onto the PBS, arguing that spending on medicines has not truly slowed, but has shifted decisively from government to consumers, reshaping how the PBS functions, what it can fund, and the policy choices now confronting decision-makers.
The PBS paradox - a rising medicine spend, but a shrinking investment capacity
January 20, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Peter Mac taps Sydney manufacturer to test its solid tumour CAR T therapy
October 14, 2026 - - Latest News -
Priceline Pharmacy puts its name on the Diamonds as netball rides record growth
October 14, 2026 - - Latest News -
'Maximising off patent medicines and why the PBS needs a biosimilar strategy'
October 14, 2026 - - Latest News -
Until the law changes what the committee is instructed to weigh, these processes will deliver nothing
October 14, 2026 - - Latest News -
The PBS stands alone as the only major health and disability program going backwards
October 13, 2026 - - Latest News -
GBMA's Nikki Lorenz returns from global generics talks with WHO and WTO
October 13, 2026 - - Latest News -
Australian children with cancer are missing out on trials adults can access
October 13, 2026 - - Latest News
